Aegis Sciences Corporation

Aegis Sciences Launches New Medication Adherence Tool for Behavioral Healthcare

Follow Us:

Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative testing and consulting services to providers, launched AcuRiseID™. A new tool that offers accurate and informative medication monitoring testing for those being treated for mental illness and substance use disorders. The test provides clinicians with valuable, objective insight that helps them identify if a patient is being consistent with their course of therapy.

AcuRiseID is cost-effective, non-invasive and can be administered during regularly scheduled appointments with doctors, clinicians, therapists, and counselors. Once the urine sample is collected, it is sent overnight to Aegis’ clinical laboratory where scientists test for medications within two distinct profiles – mental health and substance use disorder. Extensive results are ready within 96 hours and are reported via fax, a web portal or electronic medical records. Clinical pharmacists are available to interpret results and answer questions.

Monitors medication adherence in people

The AcuRiseID mental health profile tests for more than 40 medications including those used to treat schizophrenia, ADHD, anxiety, bipolar disorder, and depression. It helps clinicians understand if their patients are taking their prescribed medications for these disorders. The data also provides valuable insight into proper dosage and allows for adjustments to be made to personalize therapy plans.

AcuRiseID’s substance use disorder profile includes more than 30 drugs including amphetamines, benzodiazepines, and opioids. It helps clinicians know if their patients are taking substances – prescribed or illicit – that may hinder their recovery.

Clinicians can personalize testing orders for different use-cases to best fit their needs. This is especially important when treating individuals with co-occurring mental illness and substance use disorders. It is estimated that 10.2 million adults with a substance use disorder have a co-occurring mental illness.

CEO of Aegis, Dr. Frank Basile said “There are incredibly effective therapies for even the most serious mental illnesses, but no medication can be effective if it isn’t taken. Similarly, recovery from substance abuse can be derailed by taking the wrong medications. AcuRiseID is a valuable tool for clinicians working with those with behavioral health disorders. It takes conjecture out of conversations about therapeutic adherence, helping people and their providers have more productive conversations about their challenges and concerns.”



Subscribe To Our Newsletter

Get updates and learn from the best

Scroll to Top

Hire Us To Spread Your Content

Fill this form and we will call you.